Edwards Lifesciences (NYSE:EW) traded lower in the premarket on Thursday after Wolfe Research downgraded the heart device ...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”) ...

(Yicai) Nov. 10 -- There is still much work to be done to bring transcatheter aortic valve replacement, which is a minimally invasive procedure to replace the aortic valve, to China, an executive at ...

We report a technique for the enlargement of a hypoplastic aortic root by an operation whereby the hypoplastic aortic root has been so enlarged by the insertion of a Dacron fabric gusset that it will ...

Edwards enters 2025, its first full year as a purely structural heart company, in a strong position with major growth drivers in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter ...

Edwards Lifesciences cut sales-growth estimates for its biggest source of revenue, a heart valve replacement treatment. The heart disease and critical care monitoring company also missed ...

Edwards Lifesciences Corp ... Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart ...

Wedgewood Partners, an investment management company, released its fourth-quarter 2024 investor letter. A copy of the letter ...

Wolfe Research downgraded Edwards Lifesciences (EW) to Underperform from Peer Perform with a $60 price target The firm says its core ...

Major Growth Drivers Transcatheter Aortic Valve Replacement (TAVR ... Surgical Therapies: Edwards plans to expand the adoption of its RESILIA portfolio, which includes innovative solutions ...